Provided by Tiger Fintech (Singapore) Pte. Ltd.

Aptose Biosciences

1.71
+0.0000
Volume:- -
Turnover:- -
Market Cap:4.36M
PE:-0.05
High:1.71
Open:1.71
Low:1.71
Close:1.71
Loading ...

Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML

GlobeNewswire
·
10 Dec 2024

Aptose Biosciences Price Target Maintained With a $2.00/Share by HC Wainwright & Co.

Dow Jones
·
04 Dec 2024

Aptose Biosciences signs CRADA with NCI to develop tuspetinib for AML, MDS

TIPRANKS
·
03 Dec 2024

Aptose Biosciences Boosts Capital with $8M Offering

TIPRANKS
·
26 Nov 2024

Aptose Biosciences Inc. Announces Closing of $8 Million Public Offering

GlobeNewswire
·
26 Nov 2024

Dow Jumps 300 Points; Gap Posts Upbeat Earnings

Benzinga
·
22 Nov 2024

Aptose Biosciences Prices $8 Million Securities Sale

MT Newswires Live
·
22 Nov 2024

Aptose Biosciences Announces $8 Million Public Offering

TIPRANKS
·
22 Nov 2024

Aptose Biosciences Inc. Announces Pricing of $8 Million Public Offering

GlobeNewswire
·
22 Nov 2024

Aptose Biosciences Initiates Phase 1/2 Study for Newly Diagnosed Acute Myeloid Leukemia Patients

MT Newswires Live
·
21 Nov 2024

Aptose Biosciences price target lowered to $2 from $7 at H.C. Wainwright

TIPRANKS
·
20 Nov 2024

Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy

GlobeNewswire
·
20 Nov 2024

Aptose Biosciences Reports Q3 2024 Financial Highlights

TIPRANKS
·
09 Nov 2024

Aptose Biosciences Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
09 Nov 2024

Aptose Biosciences Advances AML Triplet Therapy

TIPRANKS
·
09 Nov 2024

Aptose Biosciences Q3 2024 GAAP EPS $(0.37) Beats $(1.19) Estimate

Benzinga
·
09 Nov 2024

Aptose Reports Results for the Third Quarter 2024

GlobeNewswire
·
09 Nov 2024

Aptose Biosciences Inc expected to post a loss of $1.19 a share - Earnings Preview

Reuters
·
06 Nov 2024

BRIEF-Aptose Biosciences Files Prospectus Relates To Offering Of Up To 21.5 Mln Common Shares Together With Warrants -SEC Filing

Reuters
·
31 Oct 2024

BRIEF-Aptose Biosciences On Oct 1, Got Staff Nasdaq Staff Determination Letter That Co Did Not Meet Terms Of Extension To Regain Compliance

Reuters
·
05 Oct 2024